Influenza Flu Articles & Analysis
8 articles found
MADISON, Wis., Sept. 7, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal ...
School is back in session, here’s what you need to know to help keep your family protected from flu. Influenza can be a real burden. It can spread rapidly between children and their families to have a significant impact on quality of life and disruption of usual activities: resulting in missed school days and for caregivers, missed work and illness ...
Spring is fast approaching, and coronavirus restrictions are being lifted all over the northern hemisphere. Are we ready to loosen up protection? Is there hope the virus will die in summer? With time flying unnoticed, we are already into our third summer with coronavirus being part of our lives. As of today, almost 500 million people worldwide have been in contact with SARS-CoV-2. These, of ...
The study will evaluate the safety, tolerability, and immunological response to FluGen’s investigational supra-seasonal, live, single-replication, intranasal M2SR influenza (flu) vaccine, and high dose inactivated vaccine (IIV). There is a demonstrated unmet need for improved flu vaccine options, as current injectable vaccines primarily ...
Data published in the Journal of Infectious Diseases demonstrate that M2SR can protect against a multi-seasonal, seven-year drifted influenza strain – MADISON, Wis., Aug. 2, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the publication of results from its Phase ...
Study is the Company’s first trial evaluating ability of M2SR and the current licensed standard of care to protect against drifted virus strains, and its second study in older adults, a population most vulnerable to mortality from flu – Safety and immunogenicity study expected to begin in Q2 2022 – MADISON, Wis., July 1, 2021 /PRNewswire/ — FluGen, Inc., ...
Study will measure immune responses to matched and drifted virus strains in older adults, a population that is most vulnerable to mortality from flu – Topline data expected in 1H 2022 – MADISON, Wis., May 25, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the ...
We present our methodology and stochastic discrete-event simulation developed to model the screening of passengers for pandemic influenza at the US port-of-entry airports. Our model uniquely combines epidemiology modelling, evolving infected states and conditions of passengers over time, and operational considerations of screening in a single simulation. ...